摘要
急性髓细胞白血病(AML)的发病率随着年龄的增加而上升。老年AML患者对标准化疗的反应性较年轻人差,体现在完全缓解率低、无复发生存率低、总体生存时间短。依据近年来的临床研究应该从老年AML患者独特的生物学特性和身体心理等方面因素考虑,选取个体化治疗方案,并且在恰当的时机实施以改善预后。目前,抗CD33单抗、法尼酰基转移酶抑制剂、新型核苷类似物、FMS样酪氨酸激酶3抑制剂、甲基转移酶抑制剂以及靶向治疗新药在老年AML患者中的应用正处于临床研究阶段,为治疗提供了新的方向。
The incidence of acute myelogenous leukemia（AML） increases with age.Older AML patients have poorer treatment outcomes than younger patients,as shown by a lower complete remission rate,lower relapse-free survival rate,and shorter overall survival time.According to the recent clinical researches,individualized therapy should be implemented,considering the unique biological features and physical and psychological conditions,to improve the prognosis.Recently,targeted therapies,such as CD33 monoclonal antibody,farnesyltransferase inhibitors,newer nucleoside analogues,FMS-like tyrosine kinase-3 inhibitors,and methyltransferase inhibitors are under evaluation in clinical trials of older AML patients,as a new direction.
出处
《医学综述》
2011年第6期883-886,共4页
Medical Recapitulate
关键词
急性髓细胞白血病
老年
个体化治疗
靶向治疗
Acute myeloid leukemia
Elderly
Individualized therapy
Targeted therapy
